ATAI News and Press, ATAI Life Sciences N.V. From 05/02/23

NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Aegis Virtual Conference. Details of the ...

- Pharmacodynamic profile of GRX-917 indicates potential for anxiolytic activity without the significant sedative side effects associated with benzodiazepines NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-s...

This year, the U.S. government will decide whether to approve the use of psychedelic drugs such as MDMA for the treatment of a range of mental health conditions. This milestone will not only be significant for patients in need of alternative therapies but also major players in the industry, inc...

2023-04-20 08:55:00 ET With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences (NASDAQ: ATAI) is having a rough go of things lately. Nonetheless, per bombastic predictions by Wall Street analysts,...

The psychedelic renaissance is here, with numerous studies showing that psychedelics, including LSD, psilocybin, MDMA and ketamine. may be useful in the treatment of mental health conditions , such as addiction, depression, anxiety and psychological distress. Veteran religion journalist Don La...

2023-04-13 15:36:07 ET German biotech Atai Life Sciences ( NASDAQ: ATAI ) added 12% Thursday after announcing investigators have dosed the first participant in a Phase 1 study for PCN-101, a candidate targeted at treatment-resistant depression (TRD). Atai ( ATAI ) comp...

NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been dosed in Perception Neuroscience...

The first psychedelic facilitators at the Changa Institute passed their final exams . The 13 individuals will become the first physicians in the United States to be licensed to guide patients through psychedelic experiences outside of clinical trials. A recent surge in psychedelic research has r...

2023-03-31 14:49:06 ET Shares of Atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company that is developing therapies from psychedelics to treat mental health conditions, saw its shares rise 12.41% by Friday afternoon. The stock had already been climbing a...

2023-03-31 09:53:39 ET Atai Life Sciences (NASDAQ: ATAI) , a small-cap drugmaker developing psychedelic-based treatments for drug dependency and mental health disorders, posted strong gains during the first four days of trading this week. Specifically, the biotech's stock gained...